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ABSTRACT 
Introduction: Current standard treatment of small renal masses (SRM) is surgical 
resection, but it is not plausible in all patients. Since the behaviors of SRM are not 
completely understood, the management of such lesions remains controversial. We 
evaluated the rates of linear and volumetric growth and metastasis of solid SRM in 
patients followed by active surveillance (AS). 
Materials and Methods: We performed a retrospective medical records review of 38 
patients followed by AS for solid SRM. We reviewed radiographic imaging and hospital 
records. Extracted variables included size of lesions at diagnosis and surveillance, 
duration of surveillance, available pathology and progression to metastasis.   
Results: Of the original 44 lesions, 36 lesions in 32 patients were included. Mean lesion 
size at initial presentation was 1.73cm. Mean duration of surveillance was 34.3 months. 
Benign and malignant lesions demonstrated mean linear growth rates of 0.19cm/yr vs. 
0.31cm/yr and volumetric growth rates of 0.95cm3/yr vs. 2.91cm3/yr, respectively. Seven 
patients crossed over to surgery due to patient preference or significant interval lesion 
growth. Pathology was obtained in 25% of lesions, of which 44% proved to be malignant 
renal tumors known as renal cell carcinoma (RCC). There was no correlation between 
initial lesion size and growth rate. Progression to metastasis was not seen in any of the 
subjects. Neither of two deaths during surveillance was due to renal cancer.   
Conclusions: Most enhancing SRM grow slowly, making active surveillance a safe 
alternative to surgery in nonsurgical candidates. Changes in lesion volume may be a 
better predictor of cancer cell growth than linear growth.  
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Introduction 
 
The incidental detection of small solid renal tumors (4cm or smaller) has gradually 
increased in frequency in the last two decades as a result of the widespread use of body 
imaging during work up for unrelated medical issues. Schlomer et al. (1) reported that up 
to 74% of the newly diagnosed cases of renal tumors are discovered incidentally. In 
contrast, earlier detection of these renal masses has led to a decrease in tumor size at 
presentation (2), putting practicing urologists and their patients in a difficult position to 
make clinical decisions about the management of low stage disease.  
 
Renal tumors are generally heterogeneous with an 80% potential for malignancy and 20-
25% exhibiting aggressive behavior at time of diagnosis (3). Lesions with solid 
components on ultrasound or those with enhancement on CT or MRI are considered 
malignant until proven otherwise. The most common malignant renal tumor accounting 
for 80% of all kidney tumors is renal cell carcinoma (RCC), a yellow-to-orange tumor 
that originates in the lining of the proximal convoluted tubules. Although the current gold 
standard for the treatment of enhancing solid small renal masses is surgical resection by 
nephron-sparing surgery (4), the appropriate management of small renal masses, 
especially in patients with significant surgical risk, remains controversial. Over the last 
several years, there has been significant debate on the role of active surveillance (AS) in 
management of small renal masses. Under the current general practice of active 
surveillance, patients undergo routine abdominal and pelvic imaging with CT or MRI 
with linear size monitoring of their renal tumors over time. 
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While there are studies that have reported on outcomes of active surveillance of localized 
small renal masses (5,6,7,8,9,10,11,12), these studies remain few in number, contain 
small cohorts of patients, and only investigate the linear growth of such lesions. To our 
knowledge, this is the first study to evaluate the role of volumetric change, in addition to 
change in linear size, in small renal lesions under long-term active surveillance.  
 
Types of Kidney Tumors 
Renal Cysts 
The widespread use of radiographic imaging has resulted in an increase in detection of 
benign kidney tumors. The most common benign kidney lesion is a benign simple cyst, 
accounting for over 70% of all asymptomatic renal masses. Renal cysts are found in more 
than 50% of patients over 50 years old (13), and are generally clinically insignificant. 
Cystic lesions are best characterized by ultrasound or CT scan imaging to assess for 
lesion shape, wall thickness, internal echoes and signal transmission. Renal cysts that 
meet the following criteria are characterized as benign simple cysts: 1) round or ovoid in 
shape, 2) smooth and thin cyst wall, 3) sharply demarcated, and 4) homogenous with no 
calcifications, septations, or internal echoes. Simple cysts do not enhance with 
intravenous contrast. Complex cysts, on the other hand, have an irregular shape or 
contour with evidence of calcification, internal septation, and contrast enhancement with 
contrasted CT imaging (figure 1). 
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Figure 1. Ultrasonography of renal cysts. Left: Simple renal cyst (Cy) with sharp 
interfaces with renal parenchyma, no internal echoes, and increased through signal 
transmission. Right: Complex renal cyst (arrow) with lobulated margins and thick wall. 
[From Smith’s general urology, 2008 (16)]. 
 
The Bosniak classification (16) of renal cysts can be used to differentiate the spectrum of 
simple to complex cysts, and to determine the potential risk for malignancy based on 
ultrasound imaging (figure 2):  
• Bosniak type I renal cysts, also known as benign simple cysts are homogenous, 
smooth, thin-walled lesions with distinct cyst wall-renal parenchymal interface, 
no internal echoes or signs of calcification, septation, or contrast enhancement.  
• Bosniak type II renal cysts are benign lesions ≤ 3cm in diameter. They are 
characterized as having minimal central septations (≤1 mm thick), or a thin 
peripheral calcification without contrast enhancement. 
• Bosniak IIF renal cysts contain multiple thin central septations, thickened 
peripheral calcifications, and can be hyperdense and minimally enhancing lesions. 
These lesions are minimally complex and require follow up to monitor changes in 
lesion characteristics, and carry a 20% risk for malignancy (37).  
• Bosniak III renal cysts are complex lesions with irregular borders, extensive 
calcifications and septations, and a thicker contrast enhancing cyst walls (≥1mm). 
These lesions have a high potential for malignancy (> 33%), and therefore, 
surgical resection is recommended.  
Image removed in consideration of US Copyright Law 
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• Bosniak type IV renal cysts are complex lesions with thick septations and cyst 
walls, and often contain significant calcifications. These lesions often demonstrate 
large enhancing nodules or solid components within the cystic lesion. They are 
considered malignant (> 92.5%) and should undergo surgical resection. 
 
 
Figure 2. Contrast-enhanced CT scan of renal cysts at various Bosniak stages. Top 
left: Bosniak II cyst with minimally thickened but smooth linear calcification (arrow) 
within a septum without concomitant tissue enhancement. Top right: 2-cm Bosniak IIF 
renal mass (straight arrows) with thick mural calcification (curved arrows), but no 
enhancing soft-tissue components. A Bosniak I simple cyst (C) is also present posteriorly. 
Bottom Left: Bosniak III, complex cystic lesion with thick mural calcification (straight 
arrows) and a thick, enhancing wall (curved arrow). Bottom right: Bosniak IV, complex 
cystic mass with mural calcification (long arrow), wall enhancement, and obvious 
enhancing soft-tissue components (short arrow) adjacent to the wall. [From Israel et al. 
Classification in cystic renal masses (56)].  
 
Image removed in consideration of US Copyright 
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Benign Solid Tumors 
The most common benign solid renal tumor is a renal adenoma, a small (<5mm), highly 
differentiated glandular tumor arising from the proximal tubule of the renal cortex. 
Although the radiological incidence of renal adenoma is less than 1%, these lesions have 
an incidence of 7-23% in autopsy series (14). Papillary adenomas are microscopically 
and macroscopically similar to low grade papillary RCC (defined below), however, they 
are considered benign due to the low frequency and metastatic rates of adenomas less 
than 5mm in diameter. 
 
Renal oncocytoma is another type of benign renal tumor seen in 3-7% of all solid renal 
tumors (15). Grossly, oncocytomas are light brown or tan lesions surrounded by a fibrous 
capsule and contain a central scar without necrosis. These lesions, however, cannot be 
clearly differentiated from RCC based on clinical, radiological imaging or biopsy; 
therefore they are treated as RCC until proven otherwise.  
 
Angiomyolipoma (AML) is a benign nonencapsulated, yellow-to-gray, typically round-
to-oval lesion containing various amounts of fat, smooth muscle and blood vessels. AML 
may be seen alone or in 40-80% of patients with tuberous sclerosis, an autosomal-
dominant inherited disorder characterized by adenoma sebaceum skin lesions, mental 
retardation, epilepsy and multi-organ AML (16). Presence of fat within the lesion 
signifies AML, since RCC does not contain fat. The appropriate management of AML is 
based on lesion size and patient symptoms.  AML lesions greater than 4cm are more 
likely to grow and be symptomatic (pain, hematuria, bleeding). For this reason, lesions 
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that are <4cm are generally managed conservatively while lesions >4cm or those that are 
symptomatic are treated with nephron-sparing surgery (17). 
 
Other rare benign renal tumors include leiomyomas, renal hemangiomas, lipomas and 
juxtaglomerular cell tumors. These lesions are usually clinically insignificant with the 
exception of juxtaglomerular cell tumors, which can cause significant hypertension 
secondary to renin secretion by the tumor. Leiomyomas are seen in the renal capsule and 
pelvis which contain smooth muscle. Renal hemangiomas are vascular lesions that are 
usually solitary and rarely bilateral. 
 
Malignant Tumors 
Renal cell carcinoma (figure 3) is a characteristically yellow-to-orange tumor that 
originates in the renal cortex and can extend into the perinephric tissue. Histologically 
RCCs are mixed adenocarcinomas that involve two or more tumor subtypes including 
clear cell, papillary, chromophobe, and collecting duct. Seen in 70-80% of RCC, clear 
cell subtype is the most common type of RCC and is characterized by a low nuclear-to-
cytoplasmic ratio and clear cytoplasm. Papillary (chromophil) tumor is seen in 10-15% of 
RCC and arises from the proximal tubule. Two subtypes of papillary RCC exist: low-
grade type I with a basophilic cytoplasm, and high-grade type II with an eosinophilic 
cytoplasm, which carries a worse prognosis (18). Chromophobe tumors account for less 
than 1% of RCC cases and have distinct cell borders and abundant cytoplasm that stains 
with Hale’s colloidal iron (19). Collecting duct carcinoma is a rare (<1%) but highly 
malignant tumor usually located in the renal medulla or papilla. Patients with collecting 
	   11	  
duct tumors rarely survive beyond five years, and an estimated 40% of these tumors 
present with metastasis. With the exception of collecting duct carcinoma, tumor type is 
not an independent predictor of prognosis among RCC subtypes with similar stage and 
grade. However, without regard to stage or grade, chromophobe tumors have a better 
prognosis because they are usually low stage and low grade (20). 
 
Epidemiology and Risk Factors for RCC 
Accounting for 2% of all adult malignancies, RCC is the 10th most common malignancy 
among males and the 14th most common malignancy among females. RCC is also the 3rd 
most common urologic tumor after prostate and bladder cancer (21). The incidence of 
renal cell carcinoma has been increasing steadily in the last three decades, with average 
annual percentage increase of 2-3% (22). The National Cancer Institute has estimated that 
in 2012, over 64,770 new cases of kidney cancer will be diagnosed, and over 13,570  
 
Figure 3. Renal Cell Carcinoma. (A) CT scan showing a 6-cm solid heterogeneous 
lesion of the right kidney at the inferior pole (thin arrow) with osteoblastic vertebral 
lesion (thick arrow) suggestive of metastatic disease. (B) Gross surgical specimen 
showing a well-circumscribed tumor, located at the inferior pole, with a heterogeneous 
aspect with white and yellow areas. [From Bressenot et al, 2010 (57)].  
Image removed in consideration of US Copyright Law 
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people will die from kidney cancer (23). The peak incidence of kidney cancer is among 
the 55-64 year old population, while the greatest number of deaths from kidney cancer 
has been reported among the 75-84 year old group (22). 
 
Many preventable and non-preventable factors have been associated with a higher risk for 
development of RCC, including tobacco smoking, obesity, hypertension, acquired cystic 
kidney disease and chronic renal failure, as well as genetic factors such as a von Hippel 
Lindau disease, Tuberous sclerosis, Birt-Hogg-Dube, adult polycystic kidney disease, and 
a family history of renal cancer. Of these risk factors, tobacco smoking has shown to be 
the most important in development of renal cancer and is seen in 20% of RCC cases 
(24,25). Tobacco smokers have an estimated 2.3 fold greater risk for RCC than 
nonsmokers, with a dose-response pattern with respect to the number of cigarettes (26). 
Smoking cessation decreases the risk for RCC, but their risk is not equivalent to 
nonsmokers’ risk until more than ten years after quitting tobacco (27). Chronic tissue 
hypoxia with carbon monoxide exposure and smoking related respiratory conditions such 
as chronic obstructive pulmonary disease are two mechanisms by which tobacco smoking 
increases the risk of RCC (28). Consumptions of moderate alcohol, fruits and vegetables,  
and fatty fish have been reported to reduce the risk of RCC development (29). 
 
Clinical Findings and Evaluation 
Renal tumors are often asymptomatic which explains the high rate of incidental detection 
of these tumors during abdominal imaging.  The classic triad of flank pain, gross 
hematuria, and palpable flank mass is only observed in 7-10% of cases, and often 
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signifies advanced disease (16). Other presenting signs or symptoms may include weight 
loss, fever, anemia, dyspnea, cough and bone pain secondary to distant metastasis. RCC 
is also associated with a variety of paraneoplastic syndromes including paraneoplastic 
erythrocytosis in 3-10% (30), hypercalcemia in 20% (31), hypertension (up to 40%), and 
Stauffer syndrome of hepatic dysfunction in 3-20% of patients (32). 
 
Patients suspected of having a renal tumor undergo radiographic imaging with renal 
ultrasound, CT or MRI to better characterize the lesion. Renal ultrasound is a noninvasive 
and inexpensive technique to distinguish simple cysts from solid tumors. CT scan is the 
primary imaging modality at this time because of its high sensitivity in detection of renal 
masses. MRI, although more expensive, is equivalent to CT scan for RCC staging and 
does not require contrast material or expose patients to ionizing radiation. CT imaging of 
RCC typically demonstrates a solid tumor with decreased Hounsfield units at baseline 
compared to normal renal parenchyma, which enhances with administration of 
intravenous contrast (figure 3A). In addition, patients with a suspected renal tumor should 
also receive a chest x-ray to evaluate for metastatic disease. A routine bone scan is not 
indicated in patients without bone pain since the incidence of bony metastasis in such 
patients with normal alkaline phosphatase levels is very low (33). 
 
Biopsy of Renal Masses 
The role of biopsy in management of renal masses has been limited in the past due to the 
high sensitivity of diagnostic imaging as well as the risks and complications of needle 
biopsy. Some studies also suggested that percutaneous biopsy was nondiagnostic in 10-
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15% of cases, with false negative rates of 1-2% when adequate tissues were obtained. 
Furthermore, there are rare reports of tumor seeding along the needle tract as well as 
tumor spillage in cystic lesions. Other complications of needle biopsy include hematoma, 
infection and hemorrhage, with serious side effects in < 2% of patients. For these reasons, 
percutaneous biopsy was primarily performed in patients with suspected of having 
metastatic disease, lymphoma or a renal abscess (34,35). 
 
In the last few years, however, percutaneous biopsy of renal masses has gained support in 
in follow-up surveillance and in ablative therapy. There has also been a shift in general 
recommendations as the 2012 National Comprehensive Cancer Network (NCCN) and 
2010 European Association of Urology guidelines now state that biopsy “should be 
considered before ablative and systemic therapy without previous histopathology, and in 
surveillance strategies” (36,37). The changes in recommendations are driven by the 
ability to distinguish and conservatively manage biopsy-proven benign disease (20% of 
all renal tumors) as well as improvements in accuracy and safety of renal mass biopsy. 
Although general recommendations now support percutaneous needle biopsy of renal 
masses, the decision to perform a biopsy should be made on a patient specific basis. The 
American Urology Association guidelines (2009) state that biopsy should not be 
considered in “healthy patients unwilling to accept the uncertainty associated with this 
procedure or for older patients who will only consider conservative management options 
regardless of biopsy results” (38). 
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Tumor Stage and Grade 
Staging 
Tumor stage is the most important factor in predicting prognosis of RCC and reflects the 
tumor size and extension beyond the kidney. The Tumor-Node-Metastasis (TNM) system 
describes the tumor size and direct extension (T), number of regional lymph nodes 
involved (N), and extent of distant metastasis (M). The most recent (2010) version of the 




Fuhrman nuclear grading can also be used to evaluate clear cell and papillary RCC, and is 
most effective in predicting metastasis. It is based on the tumor’s nuclear characteristics 
including size, contour and nucleoli appearance. Tumors are given a grade of 1 through 4, 
with higher grades suggesting a worse prognosis. A Fuhrman grade I tumor is 
characterized by a small nucleus, with a round, smooth and uniform contour and non-
prominent nucleoli. A grade II lesion has a medium-sized nucleus with minor contour 
irregularities and non-prominent nucleoli. Fuhrman grade III lesions have large nuclei 
with major contour irregularities and prominent nucleoli. Fuhrman grade IV lesions have 
even larger nuclei with greater contour irregularities (mutilobulted, pleomorphic) and 
prominent nucleoli.  
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Table 1. TNM classification for staging of renal cell carcinoma. [From AJCC Cancer 




Several options exist for the treatment of renal cell carcinoma and the appropriate therapy 
depends on the tumor location and stage. However, the only truly curative therapy with 
known long-term follow up is surgical excision. Therefore, surgical excision of tumor by 
nephron-sparing surgery or radical nephrectomy has become the primary treatment for 
Image removed in consideration of US Copyright Law 
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localized RCC. Surgical excision can be performed by an open approach, classic 
laparoscopic technique, or robotic-assisted laparoscopic surgery.   
 
Radical and Partial Nephrectomy 
In the past, radical nephrectomy (RN) has been the principal treatment for localized RCC. 
RN involves the removal of the entire kidney, Gerota’s fascia, perirenal fat, regional 
lymph nodes, proximal ureter, and ipsilateral adrenal gland, and has demonstrated 
excellent tumor control and disease-free survival rates (40). The significant negative 
impact of RN on renal function and its association with chronic kidney disease (41), 
however, is the main concern with this therapy and indicates the need for alternative 
treatment options. 
 
The goal of partial nephrectomy (PN) is to remove the tumor with a margin of normal 
tissue while preserving as much renal function as possible. The appropriate size of 
negative margins is controversial and has not shown to impact prognosis (42). 
Complications of PN include positive surgical margins, hemorrhage, warm ischemia and 
urine leak. However, techniques to avoid such complications can be taken including 
frozen section sampling of tumor base, hilar vessel clamping, use of mannitol and 
diuretics, cold ischemia, and careful closure of the collecting system. Although the 
absolute indications for PN include treatment of patients with poor baseline renal 
function, solitary kidney, bilateral renal tumors, or hereditary renal cancer, PN is now 
used as the primary surgical therapy for most peripherally located, clinical stage T1 renal 
tumors (tumor ≤ 7cm) (20). Studies comparing partial vs. radical nephrectomy have 
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demonstrated equivalent disease-free survival rates. Local tumor recurrence, however, is 
higher in PN (5% vs. 1%) (43), while long-term overall survival in T1 stage tumors is 




Energy-based ablative therapies such as cryoablation and radiofrequency ablation (RFA) 
exist with the goal of tumor destruction without excision. Tumor ablation can be 
performed by an open, laparoscopic, or percutaneous approach. Although some studies 
have demonstrated some short-term success with ablative therapy (46), others have 
shown greater local recurrence rates compared with partial nephrectomy, and difficulties 
with salvage tumor excision following ablative therapy (47). Moreover, long-term data 
about the efficacy of ablation therapy is still lacking. Given the greater risk of recurrence, 
ablative therapy is generally reserved for patients with small peripheral tumors or those 
who cannot tolerate surgical excision. As mentioned previously, tumor biopsy is 
recommended prior to ablative therapy.  
 
Active Surveillance  
Active surveillance (AS) with delayed or no treatment has become a viable alternative for 
treatment of clinical stage T1a renal cell carcinoma in the last several years. Indications 
for AS include elderly patients, those who do not desire intervention, those with limited 
life expectancy, and patients with significant comorbidity with surgical risk greater than 
risk of death from renal cancer (38). A short period of active surveillance with delayed 
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intervention can also be used to observe the growth rate of patients’ renal tumor with 
minimal risk of disease progression or metastasis (48). Few studies have reported on the 
growth rate of small renal masses ≤ 4cm under long-term active surveillance. A meta-
analysis by Chawla et al. reported an average growth rate of 0.28cm per year in lesions 
with a mean follow up of 34 months. They also reported progression to metastasis in 1% 
of lesions (5). In contrast, a retrospective study by Zini et al. demonstrated a 9.4% greater 
five-year cancer-specific survival in patients who underwent surgical excision compared 
to those under AS (49). Further long-term studies of small renal masses under active 
surveillance are necessary to better understand the behavior of small renal masses and 
better define the role of AS in management of these lesions.  
 
Treatment Algorithm 
Although the current gold standard for the treatment of renal tumors is surgical resection 
by radical or partial nephrectomy, there is no clear standard of care regarding the 
appropriate management of small renal tumors (clinical stage T1a). Based on the 
literature available on the behavior of clinical stage T1 tumors, expert opinions and panel 
consensus, the AUA developed an algorithm incorporating standards, recommendations 
and options for the management of small renal tumors (figure 4) (38). Urologists can 
utilize this algorithm to reach an individualized treatment plan with their patients, taking 
into consideration each individual’s preferences and comorbidities.  
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Figure 4. Treatment algorithm from AUA guidelines for management of patient 
with clinical T1 renal mass. [From Guideline for management of the clinical stage 1 
renal mass by American Urological Association, 2009 (38)]. 
 
STATEMENT OF PURPOSE & HYPOTHESIS  
The primary goal of this study is to determine the rates of linear and volumetric growth in 
small renal lesions under long-term active surveillance. A secondary goal of this study is 
to observe the rate of progression to metastasis based on the current practice at our 
institution of offering active surveillance in patients with significant comorbidities and 
surgical risk. Therefore, the hypothesis of this study is: If small renal masses (<4cm) 
demonstrate slow rates of linear and volumetric growths and metastasis, then AS is a 
reasonable and safe alternative to surgical resection for management of small renal 
tumors in elderly patients, or those with competing comorbidities or high surgical risk.  
Image removed in consideration of US Copyright Law 
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CLINICAL SIGNIFICANCE 
Currently there are only a few studies reporting on the long-term growth rates of small 
renal tumors and all involve a small cohort of subjects. Furthermore, there are no studies 
in the literature that report on the rate of volumetric growth in benign and malignant 
small renal tumors. Conceptually, monitoring a lesion’s change in volume over time is 
more reflective of the three-dimensional growth of renal tumors and is a more effective 
tool in surveillance of these tumors than linear growth evaluation. In addition, due to the 
limited literature available on the behavior on small renal masses, the appropriate 
management of such lesions is unclear. This study sheds further light on the long-term 
natural behavior of benign and malignant renal lesions and can be used by urologist to 
make informative clinical decisions with patients diagnosed with small renal tumors.  
 
METHODS 
In this retrospective study, we reviewed the medical records for 38 subjects who 
underwent outpatient active surveillance of their small solid renal mass at Yale New 
Haven Hospital between June 2001 and June 2011. The subjects’ medical records 
included all clinical notes, hospital documents, discharge summaries, operative notes, 
pathology results, and results for all radiographic imaging during the period of active 
surveillance. Surveillance imaging was scheduled every 6 to 12 months with CT or MRI. 
Subjects with delayed follow up or imaging were contacted per standard clinical care. No 
subject received additional imaging or follow up solely for this study.  
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Data Collection 
We created a database of patient information that included the following data: 
• Demographics 
• Known medical history 
• Family history of kidney disease 
• Age at initial presentation with renal mass 
• Date and results of initial and subsequent radiographic imaging 
• Number and size of lesion(s) at each follow up 
• Reason for active surveillance  
• Date and type of surgical intervention (if any) and findings 
• Pathological data (if any) 
• Metastasis (if any), and  
• Cause of death (if applicable) 
 
We included subjects with small renal masses, characterized by lesion diameter ≤ 5cm, 
demonstrating solid components and enhancement on post-contrast CT or MRI imaging.  
Subjects were screened for our inclusion criteria, which included patient age ≥ 18 years 
old, initial lesion size ≤ 5cm, period of active surveillance ≥ 6 months, and radiographic 
finding of one or more solid enhancing renal lesions. We excluded all subjects with 
benign cystic diseases, or those with hereditary renal tumor syndromes or metastasis at 
initial presentation.  
 
Once the database was completed we evaluated the following parameters for our subject 
population: 
• Mean age at diagnosis 
• Mean lesion size at presentation 
• Average number of subject comorbidity 
• Mean period of active surveillance 
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• Mean linear growth rate per year (cm/yr), and  
• Mean volumetric growth rate per year (cm3/yr), using the formula (4/3)*πr3 to 
estimate the volume for each lesion, with the assumption that most renal lesions 
are spherical in nature.  
Ø Of note, the same primary data were used for calculating mean linear 
growth rate per year and mean volumetric growth rate per year 
 
Kiavash Nikkhou performed all significant components of this research under the 
supervision of research advisor, Dr. Dinesh Singh. Kiavash Nikkhou submitted the 
application for review of the study by the Yale Institutional Review Board and Human 
Investigation Committee, reviewed all the subjects’ medical records, created the study’s 
database, performed basic statistical analysis, and wrote the manuscript that was 
submitted to the highly recognized and peer-reviewed journal “Urology” in January 2012. 
Kiavash Nikkhou and Dr. Singh met on numerous occasions to discuss the progress of 
the study and the database, and to review the written abstracts and manuscripts. The 
Urology administrative staff helped with obtaining medical records, and Dr. Maria 
Ciarleglio, a statistician for the Department of Surgery performed additional in-depth 
statistical analysis. The protocol was approved and was given a waiver of informed 
consent by the Yale Institutional Review Board and Human Investigation Committee.  
 
Statistical Analysis 
SAS, version 9.2 was used for all statistical analyses. Data was stratified by initial size, 
malignancy status, presence or absence of surgical intervention, and number of co-
morbidities. ANOVA, T-Test, and Kruskal-Wallis (K-W) non-parametric test were used 
to evaluate the equality of distributions for these variables due to the non-normal nature 
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of the data, with significance represented by p-value < 0.05. A Pearson correlation test 
was used to evaluate for any correlation among variables. Linear mixed effects models 
were used to model the repeated measures of lesion size and volume over time based on 
lesion malignancy. These plots show the model-estimated mean change in linear size and 
volume from baseline at various time points by lesion malignancy, exploring the 
significant interactions and adjusting for other variables in the model.  
 
RESULTS 
We identified a total of 36 renal lesions in the 32 subjects who met the inclusion criteria 
mentioned previously. Two subjects had two renal lesions and one subject had three 
lesions under active surveillance. The mean patient age at initial diagnosis was 70.9 years 
(median 73, range 47 to 90 years). The cohort consisted of 50% men and 50% women. 
Subjects were predominantly white (Table 1). The mean lesion size at initial diagnosis 
was 1.73cm (median 1.5, range 0.3 to 4.6cm). Six of the 36 lesions (17%) were 
malignant, 7 (19%) were benign, and 23 (64%) remain unknown. Of the 36 lesions, 33 
(91.7%) were ≤4cm at initial presentation. The mean period of active surveillance was 
34.3 months (median 22, range 6 to 97 months). Reasons for active surveillance included: 
significant patient comorbidity, patient opposition to undergo surgery, or a combination 
of both.  
 
Seven patients eventually crossed over to surgical intervention following a period of 
active surveillance. Of these, five (16%) patients underwent surgical resection and 2 (6%) 
underwent percutaneous cryoablation. Reasons for crossover to surgical intervention 
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Table 1. Demographics. Characteristics of the 32 subjects under 
 active surveillance for small renal mass. 
 
Characteristic N = 32 
Age  
       Mean – yr   70  
       <50  – no. (%)    3 (9) 
     50-65 – no. (%)    9 (28) 
     66-80 – no. (%)  12 (38) 
       > 80 – no. (%)    8 (25) 
Sex – no. (%)  
     Male    16 (50) 
     Female 16 (50) 
Race or ethnicity – no. (%)      
     White 26 (81) 
     Black   4 (13)   
     Hispanic   2 (6) 
Number of Comorbidities  
     < 2 14  (44) 
     2-5 16  (50) 
     >5   2  (6) 
Family history of renal cancer   1  (3) 
 
included patient preference without interval change in lesion size in 2 patients, of whom 
one underwent surgical resection and the other percutaneous cryoablation. Among the 5 
subjects with significant lesion growth as the reason for surgical intervention, 4 
underwent surgical resection and 1 underwent percutaneous cryoablation.  
 
Patients who underwent surgical treatment were younger (mean age of 61.4 years, 
median 57, range 47 to 80 years) compared to nonsurgical patients (mean age of 73.5 
years, median 76 years, range 47 to 90 years, p=0.01). They also demonstrated a greater 
mean lesion growth rate of 0.29cm/yr, compared with 0.08cm/yr seen in nonsurgical 
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patients (p<0.05), confirming our institution’s practice of earlier surgical intervention in 
fast growing lesions. 
 
Pathological data was obtained in 9 (25%) lesions. Surgical resection accounted for 5 and 
biopsy specimens accounted for the remaining 4 pathological samples [percutaneous 
biopsy (2), laparoscopic biopsy prior to percutaneous cryoablation (2)]. Of the 9 lesions 
with pathological confirmation, 4 (44%) proved to be RCC, 3 (33%) oncocytoma, 1 
(11%) mucinous cystadenoma, and 1 (11%) metanephric adenoma. Histological analysis 
of the four RCC lesions showed Papillary RCC in all four lesions. All RCC variants were 
low grade (Fuhrman 1 to 2). In addition to the four pathology-confirmed RCC lesions, 
two other malignant lesions were observed by radiographic imaging, of which one was a 
Bosniak III renal cyst and the other a Bosniak IV renal cyst.  
 
Linear and Volumetric Growth 
The mean linear growth rate of lesions was 0.12cm/yr (median 0.08, range -0.29 to 
1.03cm). Malignant lesions demonstrated a significantly higher mean growth rate of 
0.31cm/yr compared to benign and unknown lesions, which showed growth rates of 
0.19cm/yr and 0.05cm/yr, respectively (p=0.02). A linear mixed effects model of change 
in linear growth over time comparing benign, malignant, and unknown lesions and 
adjusting for other variables is shown in figure 5, demonstrating a greater mean growth 
rate in malignant tumors than benign tumors. There was no correlation between initial 
tumor size and growth rate in all tumors (Pearson correlation coefficient 0.01, p=0.9).  
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We also evaluated the change in tumor burden as reflected by the change in tumor 
volume per year, with the assumption that most small renal masses are spherical in 
nature. The mean increase in tumor volume per year among all lesions was 1.07m3/yr 
(median 0.22, range -7.47 to 15.29m3/yr). Malignant lesions demonstrated a more than 
three-fold greater growth in volume per year as compared with benign and unknown 
lesions (2.91cm3/yr vs. 0.95cm3/yr and 0.62cm3/yr, respectively). A linear mixed effects 
model of change in lesion volume over time comparing benign, malignant, and unknown 
lesions and adjusting for other variables is shown in figure 6, demonstrating a greater 
mean volumetric growth rate in malignant tumors than benign tumors.  
 
The three lesions that were >4cm on initial presentation had a mean growth rate of 
0.41cm/yr (median 0.45, range 0.32 to 0.45cm) as compared with 0.11cm/yr (median 
0.08, range -0.29 to 1.03cm) in lesions that were ≤4cm. The larger than 4cm lesions also 
demonstrated a greater mean change in volume per year of 5.89cm3/yr compared with 
0.63cm3/yr in lesions ≤4cm (P<0.009). These lesions were also treated more aggressively 
as demonstrated by the lower period of AS of 11.7 months vs. 36.1 months in lesions 
≤4cm. Of these three lesions, one was radiologically determined as Bosniak IV cystic 
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Figure 5. Model estimated mean change in lesion size from baseline over time by 




Figure 6. Model-estimated mean change in lesion volume from baseline over time by 
lesion malignancy status 
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Comorbidity Effect 
The mean number of comorbidities was 2.16 (median 2, range 0 to 7). Fourteen of 32 
(44%) subjects had less than two comorbidities, 16 (50%) had 2-5 comorbidities and 2 
subjects (6%) had more than 5 comorbidities (Table 1). The most prevalent comorbidities 
among the cohort were hypertension, diabetes and cardiovascular disease. Other 
comorbidities included peripheral vascular disease, COPD, renal failure, and history of 
myocardial infarction or stroke. The effect of patient comorbidity in the decision to 
undergo surgical intervention is reflected in the percentage of subjects who underwent 
surgery in each comorbidity category. There was no significant difference among patients 
with fewer than two comorbidities, of whom 35.7% underwent surgery while 64.3% did 
not (p=0.29). Among patients with 2-5 comorbidities, 18.75% underwent surgery while 
81.25% did not (p=0.01), and neither of the two subjects with >5 comorbidities 
underwent surgery (Figure 7). 
 
Mortality 
No subject in our study had metastatic disease at initial presentation, and none 
demonstrated progression to metastatic disease during their period of active surveillance. 
Two patients (6.3%) died while on active surveillance of their small renal mass, with 
none having renal cancer as the cause of death. The causes of death for these two subjects 
were reported as heart disease, and organ failure secondary to sepsis.  
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Figure 7.  Bar plot comparing percentage of subjects undergoing surgical 




The widespread use of radiographic imaging for medical diagnosis has led to a significant 
increase in the detection of renal masses, in particular small tumors in the early stages. As 
the long-term behavior of small enhancing renal masses continues to remain unclear, 
practicing urologists and patients with such tumors continue to struggle with the most 
appropriate management of such lesions. Currently, surgical excision of renal tumors is 
the only curable treatment option available. However, many patients diagnosed with 
small enhancing tumors are elderly and have significant comorbidities with significant 
surgical risk.   
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Several small, published studies have reported on their experiences with small renal 
masses. Studies supporting the role of AS argue that most SRM grow slowly and 
demonstrate that 85% of lesions less than 4cm are low grade (50). A large meta-analysis 
that included 225 lesions less than 4cm showed a mean growth rate of 0.28cm/yr and 1% 
progression to metastasis (5). Another report showed no significant difference in the 
long-term risk of progression to metastasis in patients under AS compared with those 
treated with surgical excision, cryoablation, or radiofrequency ablation (51). In contrast, 
higher metastasis rates were reported by two studies. Using the Surveillance, 
Epidemiology and End Results (SEER) data, one study demonstrated greater prevalence 
of metastasis and mortality with increasing tumor size (52). This study however, reported 
the prevalence of metastasis at presentation rather than progression to metastasis, and the 
greatest mortality and prevalence of metastasis was noted in lesions greater than 4cm. In 
another study, distal metastasis was reported in 8.2% of symptomatic RCC. This study, 
however, classifies lesions based on TNM staging rather than size, with 23% of 
symptomatic RCC having stage I, 23% stage II or III, and 54% having stage IV disease, 
and a mean tumor size of 7.3 cm (53).  
 
With the current data on active surveillance, many urologists are hesitant to incorporate 
active surveillance into their practice not only due to the fear of harming patients, but also 
because of medical-legal concerns. This study adds to the previously published data 
validating the safety of active surveillance by confirming the slow growth rate and low 
rates of progression to metastasis in small renal lesions with appropriate follow up. 
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Radiographic monitoring of small renal tumors at scheduled intervals can safely be used 
to monitor and guide the management of these lesions.  
 
The 36 lesions included in our cohort had a linear growth rate of 0.12cm/yr with a mean 
AS period of 34.3 months. Confirmed RCC lesions had a significantly greater mean 
linear growth rate compared to benign lesions (0.31 vs. 0.19 cm/yr). The 23 unknown 
lesions had a linear growth rate of 0.05cm/yr, which may suggest a benign nature of such 
tumors. Without pathological data, however, we cannot confirm such assumption, as 
small lesions with minimal growth can still be malignant. The mean growth rate of small 
renal masses among our patient population is consistent with the currently published data 
in the literature. Volpe et al. (54) reported an average of 0.1cm/yr growth in 32 lesions 
measuring < 4cm with a mean surveillance of 35 months. Wehle et al. (9) reported a 
mean growth rate of 0.12cm/yr in 29 lesions < 3.5 cm under a mean surveillance period 
of 32 months. Bosniak et al. (7) investigated the behavior of incidentally detected renal 
masses ≤ 3.5cm in 40 lesions and reported a growth rate of 0.36cm/yr with a mean 
surveillance of 39 months. These studies reported no progression to metastatic disease 
among their subject population. Our results support these studies and confirm the current 
recommendations that active surveillance may be safely practiced in patients with 
significant comorbidities or those who are poor surgical candidates where the risks of 
surgery outweigh the risks of mortality from renal cancer.     
 
This study is also the first known study to investigate changes in tumor volume over time 
and demonstrate its importance as a marker of disease progression and prognosis. 
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Although the rate of volumetric growth was obtained from the linear size measurements 
and converted using the volume formula for spheres [4/3)*πr3], it best estimates the three-
dimensional change that occurs in renal lesions that simple linear measurements does not. 
Using volume derivations improves clinical predictive value of renal tumors by providing 
the urologist with a more accurate reflection of increase in tumor burden over time, and 
can lead to better assessment of small growing malignant tumors.  
 
By evaluating the change in volume per year we can demonstrate the exponentially 
greater change in the number of cells than seen in linear measurements. For example, as a 
1-cm renal mass grows to 1.5cm in 1 year, it undergoes a 0.5cm/yr (50%) increase in 
linear size but a 1.24cm3/yr (238%) increase in volume. Although the precise number of 
renal cancer cells per cubic centimeter is unknown, one can appreciate how a relatively 
small change in the radius, when cubed to reflect the three-dimensional growth, reflects 
the exponentially greater number of cancerous cells present. With only a 50% increase in 
linear size in a year, the lesion in this example may continue to be watched with active 
surveillance, while a 238% increase in volume in that year demands a closer attention and 
may result in earlier intervention of potentially malignant tumors. 
 
According to the “two hit” Knudson hypothesis, mutations in 2 alleles are required for 
tumorigenesis. Furthermore, Michaelson et al. reported that progression to metastasis is a 
function of the number of tumor cells, with a rate of 1 metastasis per 1 billion tumor cells 
seen in breast cancer (55). Therefore, one can reasonably hypothesize that with an 
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exponential increase in the number of tumor cells, there is an exponentially greater 
potential for genetic mutations to generate aggressive-behaving cancer cells.  
 
Our data supports the advantages of evaluating volumetric growth rates during AS of 
small renal masses. Known RCC lesions demonstrated a more than three-fold greater 
increase in tumor volume (2.91cm3/yr) compared to benign lesions (0.95cm3/yr). In 
addition, lesions >4cm at presentation which are generally considered to have greater 
potential for malignancy had a significantly greater change in volume per year of 
5.89cm3/yr compared with 0.63cm3/yr in lesions ≤4cm (p<0.009). The advantage of 
evaluating volume growth over linear growth is also highlighted by the significant 
difference in the slopes of malignant and benign tumors in figures 5 vs. 6. Based on these 
arguments and the findings from our study, we strongly feel that lesion volume is a better 
indicator for disease progression than is linear diameter measurement.  
 
Active surveillance of slow growing renal lesions offers many advantages, especially in 
patients who are more likely to die of their competing comorbidities. It can also prevent 
an unnecessary procedure on an otherwise healthy and functioning kidney. Such benefit 
was observed in one patient in our cohort with two ipsilateral renal lesions measuring 
1.2cm and 0.7cm with growth rates of 0.11cm/yr and -0.08cm/yr, respectively. After a 
97-month surveillance period, this patient discontinued follow up when the final MRI 
distinguished the presence of fat within the lesions consistent with Angiomyolipoma 
(AML). Fat within the lesion was not detectable in any previous imaging. AS, in this 
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case, allowed time for the benign features in this lesion to become apparent, thus 
preventing an unnecessary surgery and future consequences of renal surgery. 
 
It is important to note that lesion sizes and descriptions for our subjects were recorded 
from radiology reports, and that a single radiologist did not review all lesions. The 
interpretation of lesion size carries an inherent margin of error based on the placement of 
the measuring cursor by the radiologist. Having a single radiologist review all 
radiographic imaging would provide a more consistent interpretation of results and 
minimize the inherent error of cursor placement. However, this study was designed to 
replicate real life experiences of practicing urologists. Other limitations of this study 
include a small subject population and the limited percentage of lesions with pathological 
data.  
 
As noted previously, the mean volumetric growth rate for the lesions in our study was 
obtained from the same data as linear growth rates because it was not initially considered 
as a primary endpoint for this study. However, after approximating the lesions volumes 
and evaluating the mean change in volume per year, volumetric data promises to be a 
better clinical predictive value than linear measurements. Studies collecting true renal 
tumor volume data are important in verifying the predictive power of volume calculations 
proposed in this study as well as to better understand the behavior of small renal tumors. 
 
Although the current gold standard for treatment of renal tumors is surgical excision, we 
strongly believe that small enhancing renal tumors are being highly overtreated. Patient 
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selection for surgery should be based on the patient’s age, risk of death from renal cancer, 
competing comorbidities, and risk of surgical morbidity or mortality. We believe that our 
data in conjunction with other published results supports the role of active surveillance as 
a reasonable alternative for management of small renal tumors (<4cm) in patients with 
greater age and competing comorbidities. With active surveillance of enhancing renal 
lesions the urologist and patient assume a calculated risk of growth and metastasis. 
However, any surgical intervention also carries a given risk of morbidity and even 
mortality. In certain patients, the risk of surgery far outweighs the risk associated with AS 
of their renal lesion.  
 
As the distinguished urologist Dr. Willet Whitmore once said, “Is cure necessary in those 
for whom it is possible, and is cure possible in those for whom it is necessary?” His 
prophetic words with respect to the overdiagnosis of prostate cancer can be applied to 
renal cancer and the current trends of overdiagnosing and overtreating of slow growing 
small renal lesions. Ultimately, it is likely that molecular biomarkers will enable us to 
better predict the behavior of renal cancers. Until such time, however, urologists should 
be mindful about the patients they are selecting for surgery and consider active 
surveillance with delayed or no treatment as a viable alternative for management of small 
renal tumors in older or high surgical risk patients. 
 
CONCLUSION 
Small enhancing renal masses grow at a slow rate of 0.12cm/yr during observation, with 
malignant lesions growing at a faster rate than benign lesions. Although linear growth has 
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been used for evaluation of lesion growth, we strongly believe that tumor volume may be 
a better predictor of disease progression as it more directly correlates with the 
exponential increase in the number of potentially cancerous cells. Active surveillance can 




RCC = Renal Cell Carcinoma 
AS = Active Surveillance 
SRM = Small renal mass 
CT = Computed Tomography 
MRI = Magnetic Resonance Imaging 
NCCN	  =	  National	  Comprehensive	  Cancer	  Network	  
AUA	  =	  American	  Urological	  Association	  
EAU	  =	  European	  Association	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  Urology	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